<DOC>
	<DOCNO>NCT00734201</DOCNO>
	<brief_summary>Randomised , double-blind , parallel group comparison four dose level V24343 placebo study effect V24343 blood pressure weight obese subject . The primary variable , change blood pressure ( BP ) pulse , assess outpatient ambulatory monitoring vital sign regular clinic monitoring . The efficacy V24343 assess measurement body weight , waist circumference , bioimpedance assessment body composition blood glucose . Assay plasma concentration V24343 blood sample collect interval dose used ass pharmacokinetics V24343 . Other safety assessment comprise routine monitoring adverse event ; concomitant medication ; clinical laboratory safety test , 12-lead electrocardiogram ( ECG ) self-completed psychiatric assessment .</brief_summary>
	<brief_title>Safety Efficacy Low Doses V24343 Obese Subjects</brief_title>
	<detailed_description />
	<criteria>Subjects must : healthy male subject age 18 60 year body mass index great equal 27 kg/m2 waist measurement &gt; 94 cm blood pressure ( BP ) within range systolic BP ( SBP ) : 90150 mmHg ; diastolic BP ( DBP ) : 4090 mmHg , base mean day time reading record 24 hour period ambulatory monitoring : willing use effective method contraception ( condom spermicidal contraceptive , sterilise ) duration study 3 month last dose study medication acceptable medical social history 12 month prior screen able comply requirement entire study give write informed consent Subjects must : receive V24343 previously suffer history anxiety depression ; abnormal result Patient Health Questionnaire 9 Profile Mood States ( see Section 6.3.4.5 ) history seizure ( exclude febrile convulsion 3 year age ) male subject whose female partner try become pregnant within 3 month last dose study medication significant medical condition history condition Investigator considers exclude subject study multiple drug allergy allergic component V24343 study medication smoker smoke 10 cigarette per day consume 28 unit alcohol per week , significant history alcohol abuse positive test alcohol drug abuse screen admission treatment period donate blood plasma excess 500 mL within 3 month screen expose new investigational agent within 3 month prior study drug administration clinically significant abnormality laboratory screen test , particularly liver function renal function test ( see Section 6.3.4.2 ) clinically relevant abnormal physical finding examination clinically relevant abnormal finding 12lead ECG include mean QTcB screen â‰¥430 msec seropositive hepatitis B , hepatitis C human immunodeficiency ( HIV ) viruses screen medical social reason participate study raise General Practitioner/primary care physician condition might increase risk individual decrease chance obtain satisfactory data , assess Investigator treatment prescription medicine within one month first dose overthecounter medicine , except paracetamol , within one week first dose</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Study effect blood pressure weight obese subject</keyword>
</DOC>